OMPT [L-sn-1-O-oleoyl-2-O-methylglyceryl-3-phosphothionate] is a metabolically-stabilized analog of Lysophosphatidic Acid (LPA) which acts as potent agonist for the LPA3 receptor. Of the two enantiomers, (2S)-OMPT is more potent than (2R)-OMPT showing 5-20 fold more activity in calcium release from LPA3-transfected Sf9 and rat hepatoma Rh7777 cells. (2S)-OMPT is also more potent in inducing calcium release, IL-6 production, and MAPK and Akt phosporylation in OVCAR3 cells.
Agonist, Lysophosphatidic Acid, Lysophospholipid
|Molecular Weight (g/mol)||
-20 °C or below
1) Lin, D. A. and J. A. Boyce (2005). “IL-4 regulates MEK expression required for lysophosphatidic acid-mediated chemokine generation by human mast cells.” J Immunol 175(8): 5430-8.
2) Zhao, C., M. J. Fernandes, et al. (2008). “Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis?” Mol Pharmacol 73(2): 587-600.
3) Qian, L., Y. Xu, et al. (2003). “Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity.” J Med Chem 46(26): 5575-8.